跳至主要内容
临床试验/NCT06066645
NCT06066645
招募中
3 期

Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite vs. iStent Infinite Alone in Subjects With Open-angle Glaucoma or Ocular Hypertension

Glaukos Corporation1 个研究点 分布在 1 个国家目标入组 230 人2023年9月14日

概览

阶段
3 期
干预措施
Travoprost Intraocular Implant
疾病 / 适应症
Glaucoma, Open-Angle
发起方
Glaukos Corporation
入组人数
230
试验地点
1
主要终点
change from baseline in mean diurnal intraocular pressure (IOP)
状态
招募中
最后更新
3个月前

概览

简要总结

Adult subjects with elevated intraocular pressure who have successfully undergone placement of iStent infinite trabecular bypass system will be randomized to receive a travoprost intraocular implant or receive a sham procedure and be followed for 12 months.

注册库
clinicaltrials.gov
开始日期
2023年9月14日
结束日期
2028年2月1日
最后更新
3个月前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • diagnosis of open-angle glaucoma or ocular hypertension
  • qualifying IOP in the study eye

排除标准

  • unmedicated (washed out) IOP of \>36 mmHg in the study eye
  • hypersensitivity to travoprost or any other components of the travoprost intraocular implant
  • vertical cup/disc ratio \> 0.8 in the study eye
  • best spectacle corrected visual acuity of worse than 20/80 in either eye eye
  • any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

研究组 & 干预措施

iDose TR

Travoprost Intraocular Implant in subjects who had successful iStent infinite placement

干预措施: Travoprost Intraocular Implant

iDose TR

Travoprost Intraocular Implant in subjects who had successful iStent infinite placement

干预措施: iStent infinite

sham procedure

Sham surgical procedure in subjects who had successful iStent infinite placement

干预措施: Sham procedure

sham procedure

Sham surgical procedure in subjects who had successful iStent infinite placement

干预措施: iStent infinite

结局指标

主要结局

change from baseline in mean diurnal intraocular pressure (IOP)

时间窗: 3 months

mean diurnal IOP at the 3 month visit minus mean diurnal IOP at baseline

研究点 (1)

Loading locations...

相似试验